Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly pill aims to keep weight off after obesity treatment

NCT ID NCT07553299

Ongoing Disease control Sponsor: Verdiva Bio Dev Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study tests a weekly oral medication called ecnoglutide (VRB-101) to see if it can help people with obesity or overweight maintain their weight. Participants must have already been on weekly injections of semaglutide or tirzepatide for at least 6 months. The goal is to find the best dose for weight maintenance while monitoring safety and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT WEIGHT MAINTENANCE

Contacts and locations

Locations

  • Clinical Study Site 201

    Little Rock, Arkansas, 72205, United States

  • Clinical Study Site 202

    Cullman, Alabama, 35055, United States

  • Clinical Study Site 203

    Phoenix, Arizona, 85028, United States

  • Clinical Study Site 204

    Bradenton, Florida, 34209, United States

  • Clinical Study Site 205

    Buffalo, New York, 14217, United States

  • Clinical Study Site 206

    Lenoir, North Carolina, 28645, United States

  • Clinical Study Site 207

    Richmond, Virginia, 23226, United States

  • Clinical Study Site 209

    Jackson, Tennessee, 38305, United States

  • Clinical Study Site 210

    Petal, Mississippi, 39465, United States

  • Clinical Study Site 211

    Houston, Texas, 77040, United States

  • Clinical Study Site 212

    Tempe, Arizona, 85281, United States

  • Clinical Study Site 213

    El Dorado, Kansas, 67042, United States

  • Clinical Study Site 214

    Santa Maria, California, 93454, United States

  • Clinical Study Site 215

    St. Petersburg, Florida, 33704, United States

  • Clinical Study Site 216

    Stamford, Connecticut, 06905, United States

  • Clinical Study Site 217

    Houston, Texas, 77008, United States

  • Clinical Study Site 218

    Irving, Texas, 75063, United States

  • Clinical Study Site 219

    Niles, Illinois, 60714, United States

  • Clinical Study Site 220

    Oklahoma City, Oklahoma, 73111, United States

  • Clinical Study Site 221

    Orange City, Florida, 32763, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.